Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5,7-dihydroxytryptamine is a synthetic tryptamine derivative with hydroxyl groups at positions 5 and 7 of the indole ring. It is a neurotoxic analogue of serotonin and is used in neuropharmacological research. Its mechanism involves selective uptake into serotonergic neurons via the serotonin transporter, where it undergoes auto-oxidation to produce reactive quinonoid intermediates, leading to the destruction of serotonergic neurons. It also depletes norepinephrine, though less selectively unless co-administered with a norepinephrine transporter inhibitor (e.g., desmethylimipramine). The compound is used predominantly as an experimental tool for studying the function of serotonin in the central nervous system and assessing the effects of serotonin depletion[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5,7-dihydroxytryptamine.